144 related articles for article (PubMed ID: 30990212)
1. Study on the Significance of Folate Receptor-Mediated Staining Solution (FRD) Staining in Screening High Grade Cervical Lesions.
Xiao S; Xie H; Zhu X; Li X; Yi S; Deng X; Xue M
Med Sci Monit; 2019 Apr; 25():2792-2801. PubMed ID: 30990212
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of novel folate receptor-mediated staining solution detection (FRD) for CIN2+: A systematic review and meta analysis.
Li YX; Luo HX; Wang W; Wang Z; Zhao WH; Hao M
Medicine (Baltimore); 2021 May; 100(20):e26004. PubMed ID: 34011097
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of novel folate receptor-mediated staining solution detection (FRD) for cervical cancer screening.
Dai Y; Wang L; Li D
Medicine (Baltimore); 2018 Aug; 97(34):e11868. PubMed ID: 30142780
[TBL] [Abstract][Full Text] [Related]
4. Compare two different usages of FRD for detecting high-grade cervical lesions and invasive cancer.
Dai Y; Wang L; Li D
Arch Gynecol Obstet; 2019 May; 299(5):1399-1404. PubMed ID: 30838444
[TBL] [Abstract][Full Text] [Related]
5. Clinical Application of Folate Receptor-Mediated Staining Solution Detection in Cervical Cancer Screening.
Qi W; Lv Q; Ma L; Tian W
Ann Clin Lab Sci; 2020 Jan; 50(1):73-78. PubMed ID: 32161014
[TBL] [Abstract][Full Text] [Related]
6. Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical Cancer Screening?
Gao K; Eurasian M; Zhang J; Wei Y; Zheng Q; Ye H; Li L
Gynecol Obstet Invest; 2015; 80(3):153-63. PubMed ID: 25832290
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of folate receptor-mediated tumor detection as a triage tool in cervical cancer screening.
Zhao Y; Li M; Li Y; Lv Q; Chen F; Li B; Zhang Z; Guo H; Lu D; Wang F; Zhai J; Feng L; Lai A; Li H; Yao C; Wei L
Int J Gynaecol Obstet; 2020 Sep; 150(3):379-384. PubMed ID: 32471000
[TBL] [Abstract][Full Text] [Related]
8. The clinical research of Thinprep Cytology Test (TCT) combined with HPV-DNA detection in screening cervical cancer.
Liu Y; Zhang L; Zhao G; Che L; Zhang H; Fang J
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):92-95. PubMed ID: 28364788
[TBL] [Abstract][Full Text] [Related]
9. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
10. Application of human papillomavirus in screening for cervical cancer and precancerous lesions.
Wang JL; Yang YZ; Dong WW; Sun J; Tao HT; Li RX; Hu Y
Asian Pac J Cancer Prev; 2013; 14(5):2979-82. PubMed ID: 23803065
[TBL] [Abstract][Full Text] [Related]
11. Folate receptor-mediated cervical staining as an adjunct to colposcopy which can improve the diagnostic accuracy of detecting high grade squamous intraepithelial lesions.
Homola W; Pomorski M; Zimmer A; Baranski P; Zimmer M
Ginekol Pol; 2020; 91(5):247-250. PubMed ID: 32495929
[TBL] [Abstract][Full Text] [Related]
12. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
14. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
15. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.
Sun P; Song Y; Ruan G; Mao X; Kang Y; Dong B; Lin F
J Gynecol Oncol; 2017 Sep; 28(5):e50. PubMed ID: 28657218
[TBL] [Abstract][Full Text] [Related]
17. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
18. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
20. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
